S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed stage IV carcinoma of the breast * HER-2 negative * 0 or 1+ DAKO (2+ DAKO allowed if fluorescence in situ hybridization \[FISH\] negative) * Weak or no staining on immunohistochemistry test * No amplification by FISH * No effusions or ascites as only site of disease * No brain or CNS disease or metastases * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age: * Not specified Sex: * Female Menopausal status: * Not specified Performance status: * Zubrod 0-2 Hematopoietic: * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than upper limit of normal (ULN) * SGOT or SGPT no greater than 1.5 times ULN * Alkaline phosphatase no greater than 2.5 times ULN Renal: * Not specified Other: * No clinically significant pre-existing grade 2 or greater motor or sensory peripheral neuropathy unless due to cancer * No known sensitivity to E. coli-derived proteins * No prior severe hypersensitivity reaction to drugs formulated with polysorbate 80 * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy other than 1 prior adjuvant or neoadjuvant chemotherapy program for primary disease * At least 6 months since prior chemotherapy * Prior adjuvant anthracycline allowed * No prior taxanes (docetaxel or paclitaxel) Endocrine therapy: * Prior adjuvant hormonal therapy for metastatic disease allowed * No concurrent hormonal therapy Radiotherapy: * At least 3 weeks since prior radiotherapy Surgery: * At least 2 weeks since prior surgery and recovered